Paclitaxel 30, 100, 300

Paclitaxel 30, 100, 300
Product Description

PT. Fonko international Pharmaceuticals offers a wide range of oncology finished dosage which includes Paclitaxel 30 mg, 100 mg and 300 mg. Indication : Ovarian carcinoma, Breast carcinoma, Advanced non-small cell lung carcinoma, AIDS-related Kaposi's sarcoma. Contact us for more information

Read more Show less

PT FONKO INTERNATIONAL PHARMACEUTICALS

  • On CPHI since:
    2025
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
View company profile
Categories
more categories Show less
Specifications
  • Details
    Concentrate solution for infusion
  • Selling Points
    Halal Ingredients; International Approvals/Standards; Price; Quality Service; PT. Fonko international Pharmaceuticals offers a wide range of oncology finished dosage which includes Paclitaxel 30 mg, 100 mg and 300 mg. Indication : Ovarian carcinoma, Breast carcinoma, Advanced non-small cell lung carcinoma, AIDS-related Kaposi's sarcoma. Contact us for more information
  • Model
    Concentrate solution for infusion
  • Supplied from
    Indonesia
  • Measured In
    piece
More specifications Fewer specifications
Sales Markets
Show more Show less

PT FONKO INTERNATIONAL PHARMACEUTICALS

  • On CPHI since:
    2025
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
View company profile

More Products from PT FONKO INTERNATIONAL PHARMACEUTICALS (2)

  • Bendamustine 25, 100

    Product Bendamustine 25, 100

    PT. Fonko international Pharmaceuticals offers a wide range of oncology finished dosage which includes Bendamustine 25 mg and 100 mg. Indication : Chronic lymphocytic Leukemia, Non-Hodgin Lymphoma and Multiple Myeloma. Contact us for more information.
  • Bortezomib 1, 3.5

    Product Bortezomib 1, 3.5

    PT. Fonko international Pharmaceuticals offers a wide range of oncology finished dosage which includes Bortezomib 1 mg, 3.5 mg Indication : multiple myeloma, mantle cell lymphoma. Contact us for more information.